4baseCare will utilise the funds for expansion of the genomic tests portfolio
4baseCare, an Illumina Accelerator backed precision oncology start-up, has raised an investment of $2 million, led by investors Mount Judi Ventures, growX Ventures, Season Two Ventures, First In Ventures and a few strategic angel investors. The investor group has a strong understanding of healthcare and technology and focuses on creating social impact through their investments.
4baseCare aims to make precision oncology a standard of care in Asia by increasing the utilisation of genomic tests in oncology and is working towards developing a first of its kind, Indian population-specific gene panel that will analyse a large number of genes for cancer-associated mutations to identify optimal treatment options leading to improved outcomes.
4baseCare will utilise the funds for expansion of the genomic tests portfolio and for increasing its geographical presence across Asia. Additionally, it will also focus on strengthening its R&D and operations.
Hitesh Goswami CEO, 4baseCare says, “Access to advanced technology, which can help improve treatment and care should be for everyone. Our vision is to leverage technology to develop affordable solutions to personalize patient care in oncology”.
Kshitij Rishi, COO, 4baseCare says, “With this capital, we will be increasing the affordability of our genomic test portfolio through research and process efficiency. With our comprehensive solutions and global collaborations, we are confident that we will make precision medicine a standard of cancer care in our country.”
Sherif Kottapurath, Managing Partner of MJV and Ex-CTO of Sun Microsystems says, “We are delighted that 4baseCare, with its innovative and life-critical suite in precision oncology, is the second investment by Mount Judi India Growth Fund in the healthcare vertical. We are happy that in this funding round, 4baseCare was able to attract a strong consortium of investors from India and the US, which will fuel its growth across and beyond India.”
Manu Rikhye, Partner at growX Ventures said “4baseCare team is leveraging its deep expertise in genomics to enable timely cancer diagnosis, and help identify the most precise targeted therapies to significantly improve patient outcomes. We look forward to working with this exceptional founding team as they work towards making India healthier.”
Sajan Pillai, CEO and Managing Partner of Season Two Ventures said, “Genomics and other data capabilities are now redefining life sciences. Their quest to make precision oncology more affordable and accessible contributes greatly to the growing biotech space in India & globally and we are happy to support them in their journey.”
